HCW Biologics (HCWB) investor relations material

Executive summary

• Annual Meeting scheduled for June 15, 2026, with five key proposals including director elections, auditor ratification, a reverse stock split, and approvals related to warrant exercises and repricing.

• Achieved $6.5 million in revenue for Q1 2026, driven by a new licensing agreement and upfront fees.

• Reported net income of $3.5 million for Q1 2026, a turnaround from a $2.2 million loss in Q1 2025.

• Advanced clinical pipeline with ongoing Phase 1 trial for HCW9302 in alopecia areata; no dose-limiting toxicities reported.

• Published data on HCW9206, highlighting its potential to improve CAR-T cell therapy manufacturing and efficacy.

Financial highlights

• Q1 2026 revenue increased to $6.5 million from $5,065 in Q1 2025, primarily from licensing deals.

• Net income for Q1 2026 was $3.5 million, compared to a net loss of $2.2 million in Q1 2025.

• R&D expenses decreased 15% year-over-year to $1.3 million, mainly due to lower manufacturing and clinical costs.

• G&A expenses fell 18% year-over-year to $1.8 million, reflecting reduced stock-based compensation and bonus accruals.

• Net income per share for Q1 2026 was $0.37, compared to a loss of $1.97 per share in Q1 2025.

Outlook and guidance

• Board recommends voting FOR all proposals, emphasizing the necessity of the reverse stock split to retain Nasdaq listing.

• Preliminary clinical data for HCW9302 expected in H1 2026, with full Phase 1 data in Q4 2026.

• Substantial doubt exists regarding ability to continue as a going concern for 12 months without additional funding.

• Awaiting Nasdaq decision on appeal regarding minimum bid price compliance.

• Failure to approve the reverse split may result in delisting, impacting liquidity and access to capital markets.